Worldwide Clinical Trials appoints vp, Oncology Medical Affairs

Gerald Messerschmidt joins firm from Talon Therapeutics

Worldwide Clinical Trials, a US provider of clinical research services based in King of Prussia, PA, has appointed Gerald Messerschmidt as vice president, Oncology Medical Affairs.

Messerschmidt has more than 20 years’ clinical and operational leadership in the development of critical therapies for a multitude of oncology indications, the firm said. His portfolio of experience includes small molecules, biologic products, medical devices, genetic modification of living organisms and immune modulation therapy.

Prior to joining Worldwide Clinical Trials, Messerschmidt held the position of vp, Clinical Development at Talon Therapeutics (formerly Hana Biosciences) where he co-led the successful development of Marqibo, a new liposome plus vincristine product. From 2008–2010, Messerschmidt held senior positions within oncology at Onyx Pharmaceuticals and Icon Clinical Research, preceded by leading Wild-Type Enterprises as chairman and ceo from 2000–2008.

You may also like

Regulatory

ECHA adds two hazardous chemicals to list of substances of very high concern

Companies are responsible for managing the risks of these chemicals and giving customers and consumers information on their safe use
Regulatory

NHS, MHRA and Medicines UK launch Project Revive to tackle medicine shortages

NHS England, the MHRA and Medicines UK have launched Project Revive, a collaborative pilot designed to address critical medicines shortages by fast-tracking dormant MHRA-approved licences and creating dedicated NHS purchasing arrangements to improve long-term supply resilience
Regulatory

En Carta Diagnostics bags FDA Breakthrough Device Designation for EC Pocket Lyme test

The rapid, Point-of-Need molecular diagnostic platform will fill a critical gap in early-stage detection of Borrelia bacteria, the cause of Lyme disease
Regulatory

testo Saveris 1 update automates environmental monitoring workflows for pharma compliance

Testo Saveris, global leader in measurement solutions, has announced the latest software update for its testo Saveris 1 Environmental Monitoring System, designed to address the evolving needs of the pharmaceutical industry by delivering reliable and precise monitoring of key metrics, including temperature and humidity
Regulatory

FDA accepts first quality control standard for mesenchymal stromal cells

The FDA has accepted the first dedicated quality control protocol for mesenchymal stromal cells, recognising the Tasly 3P Characterisation Assay and setting a new regulatory benchmark for MSC safety and clinical performance
Regulatory

3PBIOVIAN secures French CIR certification for Spain and Finland R&D sites

The CDMO has obtained French Crédit d’Impôt Recherche (CIR) certification for its Pamplona and Turku sites, enabling French partners to access tax incentives when collaborating on recombinant protein and advanced therapy projects
Regulatory

Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV

Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
Subscribe now